U.S. patent application number 10/845044 was filed with the patent office on 2004-10-28 for tagetes erecta marigolds with altered carotenoid compositions and ratios.
Invention is credited to Blowers, Alan, Hauptmann, Randal, Smyser, Cheryl M., Winner, Blair L..
Application Number | 20040216194 10/845044 |
Document ID | / |
Family ID | 26876629 |
Filed Date | 2004-10-28 |
United States Patent
Application |
20040216194 |
Kind Code |
A1 |
Hauptmann, Randal ; et
al. |
October 28, 2004 |
Tagetes erecta marigolds with altered carotenoid compositions and
ratios
Abstract
A marigold plant, a regenerable portion thereof and seed are
disclosed whose flower petals, leaves or flower petals and leaves
contain one or more of an enhanced zeaxanthin ratio, an enhanced
neoxanthin plus violaxanthin ratio, an enhanced .beta.-carotene
ratio, an enhanced .alpha.-cryptoxanthin ratio, an enhanced
phytoene ratio or an enhanced phytofluene ratio relative to that
ratio in a non-mutant marigold. The flower petals of such a plant
also typically contain zeta-carotene that is not normally found in
such petals. Also disclosed are methods of preparing such plants,
oleoresins and comestible materials that have such carotenoid
ratios.
Inventors: |
Hauptmann, Randal; (Oswego,
IL) ; Winner, Blair L.; (Ventura, CA) ;
Blowers, Alan; (St. Charles, IL) ; Smyser, Cheryl
M.; (Napeville, IL) |
Correspondence
Address: |
WELSH & KATZ, LTD
120 S RIVERSIDE PLAZA
22ND FLOOR
CHICAGO
IL
60606
US
|
Family ID: |
26876629 |
Appl. No.: |
10/845044 |
Filed: |
May 13, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10845044 |
May 13, 2004 |
|
|
|
10180775 |
Jun 26, 2002 |
|
|
|
6784351 |
|
|
|
|
60302460 |
Jun 29, 2001 |
|
|
|
Current U.S.
Class: |
800/323 |
Current CPC
Class: |
A01H 5/02 20130101; C12N
15/8243 20130101 |
Class at
Publication: |
800/323 |
International
Class: |
A01H 005/00 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 27, 2002 |
WO |
PCT/US02/20633 |
Claims
1-32. (Cancelled).
33. A composition suitable for use as a food or feed supplement
that comprises a mixture of zeaxanthin and lutein dissolved or
dispersed in a comestible medium, wherein the zeaxanthin ratio is
greater than about 1:10.
34. The composition according to claim 33 wherein the zeaxanthin
ratio is greater than about 2:10.
35. A composition suitable for use as a food or feed supplement
that comprises a mixture of fatty acid esters of zeaxanthin and
lutein dissolved or dispersed in a comestible medium, wherein the
zeaxanthin ratio that is greater than about 1:10.
36. The composition according to claim 35 wherein the zeaxanthin
ratio is greater than about 2:10.
37. The composition according to claim 35 wherein said comestible
medium is an edible oil.
38. The composition according to claim 35 wherein said comestible
medium is a pharmaceutically acceptable binding agent.
39-43 (Cancelled).
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority from U.S. Ser. No.
60/302,460, filed Jun. 29, 2001.
TECHNICAL FIELD
[0002] The present invention relates to a marigold plant that
contains carotenoid pigments present at other than the usual
ratios. The invention more particularly relates to a marigold
plant, a regenerable portion thereof, a hybrid or later generation
whose petals, leaves or both petals and leaves, contain an enhanced
ratio of one or more carotenoid compounds relative to lutein, and
also seed that produces such a marigold plant, an oleoresin
produced from such flowers or leaves and comestible products made
using zeaxanthin and lutein. The flower petals of such a
contemplated marigold typically also contain a measurable amount of
zeta-carotene, a compound not normally found in marigold flower
petals.
BACKGROUND OF THE INVENTION
[0003] Numerous epidemiological studies in various populations have
shown that consumption of substantial amounts of fruits and
vegetables rich in carotenoids can reduce the risk of acquiring
several types of cancers. As a result, scientists have been
focusing on investigating the protective effect of carotenoids such
as beta-(.beta.-)carotene in prevention of cancer, cardiovascular
and eye diseases. These studies have been carried out despite the
fact that .beta.-carotene is only one of the prominent carotenoids
found in fruits and vegetables whose consumption has been
associated with health benefits. The reasons for such focus can be
attributed to the pro-vitamin A activity of .beta.-carotene and the
limited commercial availability of other prominent food
carotenoids.
[0004] Among the 40 to 50 carotenoids that are available from the
diet and may be absorbed, metabolized, or utilized by the human
body, only 13 carotenoids and 12 of their stereoisomers are
routinely found in human serum and milk. [See Khachik et al., Anal.
Chem., 69:1873-1881 (1997).] In addition, there are 8 carotenoid
metabolites and one stereoisomer in human serum or plasma that
result from a series of oxidation-reduction reactions of three
dietary carotenoids: lutein, zeaxanthin and lycopene. These
metabolites were first isolated and characterized by Khachik et al.
[See Khachik et al., Anal. Chem., 64:2111-2122 (1992).]
[0005] In another study, the ingestion of purified supplements of
dietary (3R,3'R,6'R)-lutein and (3R,3'R)-zeaxanthin was shown to
not only result in an increase in the blood levels of these
compounds in humans, but also in an increase in the concentration
of their oxidative metabolites in plasma. [See Khachik et al., J.
Cellular Biochem., 22: 236-246 (1995).] These findings provided
preliminary evidence that carotenoids may function as antioxidants
in disease prevention. In addition, these results also established
the importance of non-vitamin A-active dietary carotenoids,
particularly, lutein, zeaxanthin, and lycopene.
[0006] There is increasing evidence that the macular pigment
carotenoids, lutein and zeaxanthin, may play an important role in
the prevention of age-related macular degeneration (ARMD), cataract
formation, and other light-induced oxidative eye damage. In 1985
and 1993, Bone et al. demonstrated that the human macular pigment
is a combination of lutein and zeaxanthin, and speculated that
these dietary carotenoids may play a role in the prevention of an
eye disease ARMD. [See Bone et al., Vision Research, 25:1531-1535
(1985) and Bone et al., Invest. Ophthalmol. Vis. Sci., 34:
2033-2040 (1993).] Further work in a case-controlled
epidemiological study in which the high consumption of fruits and
vegetables, rich specifically in lutein and zeaxanthin was
correlated to a 43 percent lower risk of ARMD later confirmed that
speculation. [See Seddon et al., J. A. Med. Assoc., 272(18)
1413-1420 (1994).] It has also been reported that an increased
level of serum carotenoids other than .beta.-carotene is associated
with a lower incidence of heart disease. [See Morris et al., J.
Amer. Med. Assoc., 272(18):1439-1441(1994).]
[0007] Bernstein et al. identified and quantified the dietary
carotenoids and their oxidative metabolites in all tissues of the
human eye and reported that nearly all ocular structures examined
with the exception of vitreous, cornea and sclera had quantifiable
levels of dietary (3R,3'R,6'R)-lutein, zeaxanthin, their
geometrical (E/Z) isomers, as well as their metabolites, (3R,
3'S,6'R)-lutein (3'-epilutein) and
3-hydroxy-beta,epsilon-caroten-3'-one. In the iris, these pigments
were thought likely to play a role in filtering phototoxic
short-wavelength visible light and to act as antioxidant in the
ciliary body. Both mechanisms may be operative in the retinal
pigment epithelium/choroid (RPE/choroids). [See Bernstein et al.,
Exp. Eye Research, 72 (3): 215-223 (2001].]
[0008] A study of the distribution of macular pigment stereoisomers
in the human retina identified (3S,3'S)-zeaxanthin in the adult
retina, particularly in the macula. It was proposed that dietary
lutein and zeaxanthin are transported into an individual's retina
in the same proportions found in the blood serum, although the two
pigments are present in the eye in ratios different from those
found in the blood. Thus, zeaxanthin predominates over lutein by a
ratio greater than 2:1 in the foveal region, with the macular
pigment optical density dropping by a factor of 100 and the
zeaxanthin to lutein ratio reversing to about 1:2. [See Bone et
al., Invest. Ophthalmol. Vis. Sci., 29:843-849(1988).] Some lutein
is converted into the non-dietary meso-zeaxanthin primarily in the
macula. [See Bone et al., Exp. Eye Res., 64(2): 211-218 (1997).]
Such reports lend support to the critical role of ocular
carotenoids, and therefore to the importance of commercial
production of dietary carotenoids in general, and particularly
lutein and zeaxanthin.
[0009] The Tagetes genus is a member of the family Compositae,
alternatively known as Asteraceae, and comprises some thirty
species of strongly scented annual or perennial herbs. Tagetes are
native from Arizona and New Mexico to Argentina. [See Hortus Third
A Concise Dictionary of Plants Cultivated in the United States and
Canada, MacMillan Publishing Company (1976).] Cultivated genera
include Tagetes erecta, commonly referred to as African marigold,
Tagetes patula, commonly referred to as French marigold, Tagetes
erecta x patula, commonly referred to as Triploid marigolds, and
Tagetes tenuifolia also known as Tagetes signata or signet
marigold.
[0010] A marigold inflorescence is a solitary head comprised of a
dense cluster of several hundred sessile or subsessile small
flowers also known as florets. Marigolds have radiate flower heads
with outer ray florets that are ligulate or strap-shaped around the
central tubular shaped disk florets. Some forms of marigold flower
heads have most of their disk flowers transformed into ray flowers
and contain few, if any, disk flowers. Such flower heads are
referred to as double-flowered.
[0011] The ray flowers or florets are often referred to as petals
by lay persons who may also refer to the flower heads as flowers.
For ease of understanding, marigold flower heads will be referred
to herein as flowers or flower heads, whereas the flower
head-component flowers or florets will be referred to as
petals.
[0012] Cultivated marigolds possess showy flowers and are useful
for ornamental purposes. In addition, the genus is recognized as a
source for natural colorants, essential oils, and thiophenes. Dried
marigold petals and marigold petal concentrates obtained from
so-called xanthophyll marigolds are used as feed additives in the
poultry industry to intensify the yellow color of egg yolks and
broiler skin. [See Piccalia et al., Ind. Crops and Prod., 8:45-51
(1998).] The carotenoids desired in poultry tissues are a function
of their dietary concentration, because poultry do not have the
ability to synthesize carotenoids de novo. [See Balnave et al.,
Asian-Australiasian J. Animal Sci., 9(5): 515-517 (1996).]
[0013] Xanthophyll marigolds differ in several characteristics from
ornamental marigolds. First and foremost, xanthophyll marigolds are
used as an extractable source for carotenoids and have plant habits
that differ from ornamental marigolds. Ornamental marigolds
typically grow only about 45 to about 60 cm from the ground,
whereas xanthophyll marigolds grow to about 65 to about 70 cm from
the ground. Xanthophyll marigolds grow in a bushier habit than do
ornamental marigolds, and can be grown as row crops whereas
ornamental marigolds typically cannot. Xanthophyll marigolds are
typically dark orange in color, whereas ornamentals can be white,
yellow, or orange in color, or can have mixed colors, including
mahogany colors due to the presence of anthocyanin pigments.
[0014] The pigmenting ability of marigold petal meal resides
largely in the oxygenated carotenoid fraction known as the
xanthophylls, primarily lutein esters. [See Piccalia et al., Ind.
Crops and Prod., 8:45-51 (1998).] The xanthophyll zeaxanthin, also
found in marigold petals, has been shown to be effective as a
broiler pigmenter, producing a highly acceptable yellow to
yellow-orange color. [See Marusich et al., Poultry Sci.,
55:1486-1494 (1976).] Of the xanthophylls, the pigments lutein and
zeaxanthin are the most abundant in commercially available hybrids.
Structural formulas for lutein and zeaxanthin are shown below.
1
[0015] Each of lutein and zeaxanthin contains one hydroxyl group in
each of their terminal ring structures, so that each molecule
contains two hydroxyl groups. Lutein is believed to be biologically
produced by two separate hydroxylations of .alpha.-carotene,
whereas zeaxanthin is believed to be biologically produced by two
separate hydroxylations of .beta.-carotene. Both .alpha.-carotene
and .beta.-carotene are understood to be formed by the action of
appropriate cyclase enzymes on .gamma.-carotene, which itself is
formed by cyclization of lycopene. Lycopene, .gamma.-carotene,
.alpha.-carotene and .beta.-carotene are each hydrocarbon
carotenoids.
[0016] FIG. 1 shows a schematic representation of the biological
synthesis pathway for the production of lutein and zeaxanthin and
later products from phytoene, the first C.sub.40 carotenoid in the
pathway. Lutein and zeaxanthin are present in marigold petals
primarily as mono- and di-esters of fatty acids. FIG. 1 also notes
epoxide-containing later products that can arise from zeaxanthin,
of which violaxanthin is an intermediate in the abscisic acid
biosynthetic pathway.
[0017] For the feed additive industry, xanthophyll marigolds are
produced primarily in Mexico, Peru, Africa, India, China and
Thailand. Modern, commercial varieties include `Orangeade`, one of
the original xanthophyll producing varieties, and commercial
improvements of `Orangeade`, including `Deep Orangeade` having
larger flowers and greater pigment yields, and `Scarletade` an
improvement for xanthophyll concentration. Thus, `Orangeade` is
reported to contain xanthophylls at about 9-12 mg/g of dry whole
flower heads (including calyx), `Deep Orangeade` is reported to
have about 10-13 mg/g of those pigments, and `Scarletade` is said
to contain about 12-18 mg/g of xanthophyll pigments in dry flower
heads weighed with the calyx. These varieties are available from
PanAmerican Seed Co., 622 Town Road, West Chicago, Ill. 60185.
[0018] Whereas lutein is the major xanthophyll in marigold flowers,
some current varieties yield extract products with zeaxanthin
ratios [zeaxanthin/(lutein+zeaxanthin)] typically in the 3 to 5
percent range (See Product Profile, Kemin Foods L.C., 600 E. Court
Ave. Suite A, Des Moines, Iowa 50309). As is seen from the results
hereinafter, zeaxanthin to lutein ratios obtained using
`Scarletade` are typically about 4 to about 7 percent.
[0019] Moehs et al., Plant Mol. Biol., 45:281-293 (2001) analyzed
the biosynthesis of carotenoids in ornamental varieties of T.
erecta, including a so-called wild type that had dark orange
flowers, and plants with yellow, pale yellow and white flowers.
Among other findings, those workers reported that although the
different plants had a range in flower color from white to dark
orange, the differences in those flower colors were said to be due
to the accumulation of very different amounts of the same
carotenoid, lutein, rather than to accumulation of different
carotenoid products or intermediates. The differences among the
plants studied appeared to relate primarily to regulation of flux
through the carotenoid pathway, rather than to the specific type of
carotenoid produced or the accumulation of biosynthetic
intermediates.
[0020] In addition, the so-called wild-type and mutant leaves were
reported to contain about the same quantity of carotenoid pigments,
regardless of flower color. Those pigments were different from the
pigments present in the petals. Thus, the only pigment reported for
petals was lutein, whereas the leaves were reported to contain
lutein as well as .beta.-carotene, violaxanthin and neoxanthin. As
is seen from FIG. 1, .beta.-carotene but not lutein can be a
precursor to the latter two pigments.
[0021] The Moehs et al., authors also compared the T. erecta genes
they isolated with similar carotenoid-producing genes obtained from
the leaves of Arabidopsis thaliana (Pogson et al., hereinafter).
Identities between the gene products of about 70 to about 80
percent were reported at the protein level, with a higher level if
putative plastid targeting signal peptides were excluded, and a
lower level of identity at the DNA level. In leaves of A. thaliana,
lutein is the predominant carotenoid, with .beta.-carotene,
violaxanthin and neoxanthin also being formed, but no zeaxanthin
being normally accumulated.
[0022] Carotenoid biosynthesis in T. erecta is a complex system
involving many genes and possibly two pathways. The impact of
genetic mutations on carotenoid production cannot be predicted a
priori. However, classic breeding techniques have produced
`Orangeade", `Deep Orangeade` and `Scarletade` T. erecta variants
that produce the elevated levels of xanthophylls noted above. These
relatively recently bred available varieties have not been subject
to treatments that induce genetic mutations in an attempt to
increase the zeaxanthin ratios.
[0023] Several workers have examined the effects of mutagens such
as gamma irradiation, ethyl methanesulfonate (EMS) and
nitrosomethylurea (NMU) on flowering plants, including marigolds.
For example, Zaharia et al., Buletinul Institutului Agronomic
Cluj-Napoca. Seria Agricultura 44(1): 107-114 (1991) reported on
the chlorophyll-deficient effects of carotenoids in the coleoptile
after seeds of Zinnia elegans, Tagetes erecta and Callistephus
chinensis were irradiated with gamma irradiation in varying
amounts. A paper by Geetha et al., Acta Botanica Indica,
20(2):312-314 (1992) reports on the chlorophyll deficient effects
of gamma irradiation on Tagetes patula.
[0024] Diaconu, Agronomie, 34(1):17-21 (1991) reported on the
effects of EMS on germinating seeds from F.sub.2 polycrosses of
commonly-called pot marigolds, or Calendula, that are not even of
the genus Tagetes. Those workers noted a wide variation in flower
color, inflorescence structure, yield and content of
biologically-active substances in M.sub.2-M.sub.4 plants.
[0025] A study by Pogson et al., Plant Cell, 8:1627-1639 (1996)
used EMS to mutagenize plants of Arabidopsis thaliana. This
detailed study of 4000 M.sub.2 lines reported finding two loci in
the carotenoid biosynthetic pathway in leaves that are involved
with the production of lutein from .gamma.-carotene. Those loci
were referred to as lut1 and lut2. The lut2 locus was reported to
be associated with the lycopene .epsilon.-ring cyclase enzyme,
whereas the lut1 locus was reported to be associated with the
lycopene .epsilon.-ring hydroxylase. Those workers noted (page
1631) that a decrease in lutein production was compensated for by
an equimolar change in the abundance of other carotenoids, although
only small amounts of those changes were due to an increased
production of zeaxanthin.
[0026] Cetl et al., Folia Fac. Sci. Nat. Univ. Purkynianae Brun
Biol.,21(1):5-56 (1980)reported extensive studies with T. erecta
and other Tagetes species that from the meager descriptions
appeared to all be ornamental varieties. Among those studies, those
authors examined the effects of various concentrations of NMU on T.
erecta seeds, and examined more than about 2000 plants. All M.sub.2
plants deviating from the phenotype of the parental cross were
recorded, and M.sub.3 plants from M.sub.2 seeds of the
phenotypically different plants were studied.
[0027] Those workers assayed plant height, plant diameter, flower
head diameter and height of the flower head, as well as time to
flowering, branching amount, branch length, cotyledon and leaf
size, and flower stalk length. No mention is made regarding flower
color or carotenoid levels in the leaves or petals.
[0028] Published PCT application WO 00/32788 of DellaPenna et al.
asserts of a method of regulating carotenoid biosynthesis in
marigolds. Those workers provide polynucleotide sequences said to
be those that encode the lycopene .beta.-ring cyclase and lycopene
.beta.-ring hydroxylase needed for the preparation of zeaxanthin
from lycopene. Also disclosed is a lycopene .epsilon.-ring cyclase
useful along with the lycopene .beta.-ring cyclase for the
preparation of .alpha.-carotene from lycopene. No teaching of the
lycopene .epsilon.-ring hydroxylase needed for lutein production is
provided.
[0029] Carotenoid biosynthesis is said to be regulated in PCT
application WO 00/32788 by expression of a carotenoid synthesizing
enzyme-encoding gene already present in marigolds such as those
noted above, or by use of an anti-sense RNA encoded by such a
nucleotide sequence provided. No evidence of such regulation is
provided in the application. The phenomenon known as co-suppression
by which the addition of a homologous gene causes both the native
gene and transgene not to be expressed is not dealt with by those
workers. [See for example, Fray et al., Plant Mol. Biol.,
22:589-692 (1993) or Finnegan et al., Bio/Technology, 12:883-888
(September 1994).]
[0030] An increased ratio of zeaxanthin to lutein can also provide
an attractive substrate for biotechnological production of
additional xanthophylls including the red xanthophyll, astaxanthin.
Astaxanthin is widely used as a pigmenting agent for cultured
fishes and shellfishes. The complete biomedical properties of
astaxanthin remain to be elucidated, but initial results suggest
that it could play an important role in cancer and tumor
prevention, as well as eliciting a positive response from the
immune system. [See Tanaka et al., Carcinogenesis 15(1):15-19
(1994); Jyonouchi et al., Nutrition and Cancer 19(3):269-280 (1993)
and Jyonouchi et al., Nutrition and Cancer 16(2): 93-105
(1991).]
[0031] Astaxanthin supplied from biological sources, such as
crustaceans, yeast and green algae is limited by low yield and
costly extraction methods when compared with that obtained by
organic synthetic methods. Usual synthetic methods however, produce
by-products that can be considered unacceptable. It is therefore
desirable to find a relatively inexpensive source of (3S,3'S)
astaxanthin to be used as a feed supplement in aquaculture and as a
valuable chemical for other industrial uses.
[0032] One approach to increase the productivity of astaxanthin
production in a biological system is to use genetic engineering
technology. Genes suitable for this conversion have been
reported.
[0033] For example, Misawa et al. (See U.S. Pat. No. 6,150,130)
specified DNA sequences including one isolated from the marine
bacteria Agrobacterium aurantiacus sp. nov. MK1 or Alcaligenes sp.
PC-1 that encodes a gene, referred to as crtW, used in the
production of astaxanthin from zeaxanthin as a substrate by way of
4-ketozeaxanthin. Kajiwara et al. (See U.S. Pat. No. 5,910,433)
identified a polynucleotide molecule, referred to as bkt, isolated
from Haematococcus pluvialis that encodes a polypeptide having a
beta-C-4-oxygenase activity for the production of
(3S,3'S)astaxanthin from a host microorganism or a plant. In
addition, Hirschberg et al. (See U.S. Pat. No. 5,965,795) described
another DNA gene sequence from Haematococcus pluvialis, referred to
as crtO, that encodes an enzyme that synthesizes astaxanthin from
zeaxanthin by way of 4-ketozeaxanthin. Still further, Cunningham
(See WO 99/61652) reported isolation of a DNA that encodes a
protein having ketolase enzyme activity from Adonis aestivalis, a
plant species having deep red flower color due in part to the
accumulation of the ketocarotenoid astaxanthin.
[0034] It would therefore be useful if a marigold plant could be
provided whose flower petals or leaves or both contain a
commercially useful amount of xanthophylls and an altered ratio of
lutein and zeaxanthin such that the usually reported 4 to about 7
percent zeaxanthin level were raised and the amount of lutein were
decreased. It would also be useful if the ratios of other pigments
could also be raised, and if such a plant had substantially the
same phenotypical characteristics as a usual marigold plant grown
adjacent to it. The present invention provides several such plants,
flower petals, leaves, seed that produce them, hybrids, oleoresins,
mixtures of zeaxanthin and lutein, and comestible materials
containing zeaxanthin, lutein, .alpha.-cryptoxanthin,
antheraxanthin, neoxanthin and violaxanthin, and .beta.-carotene
dissolved or dispersed in a comestible medium.
BRIEF SUMMARY OF THE INVENTION
[0035] The present invention contemplates marigold plants whose
petals, leaves or both flower petals and leaves contain one or more
of an enhanced zeaxanthin ratio, an enhanced neoxanthin plus
violaxanthin ratio, an enhanced .beta.-carotene ratio, an enhanced
.alpha.-cryptoxanthin ratio an enhanced phytoene ratio or an
enhanced phytofluene ratio compared to such a ratio present in a
non-mutant marigold. In addition, the flower petals typically
contain a measurable amount of zeta-carotene (.zeta.-carotene),
whereas that compound is not measurable; i.e., is present at less
than 0.1 percent, in the petals of a non-mutant marigold plant.
[0036] A stated ratio is determined as a percentage of the
first-named pigment divided by the sum of the percentages of that
pigment and lutein as determined by chromatographic techniques
discussed hereinafter. Thus, the zeaxanthin ratio is illustratively
defined herein as zeaxanthin/(zeaxanthin+lutein).
[0037] Preferably the petals, leaves or both the petals and leaves
of such a plant at least exhibits a zeaxanthin ratio greater than
about 1:10, preferably greater than about 2:10, up to about 1.0.
That ratio can be up to one because lutein cannot be detected in
some leaves. In some embodiments, the flower from which the petals
are taken has a xanthophyll content of about 4 to about 25 mg/g dry
weight, whereas in other plants the petal xanthophyll content can
be lower. The xanthophyll content of leaves is typically about 0.5
to about 1.25 mg/g dry weight. The flower petals and leaves are
typically present in comminuted form.
[0038] The plant that produced the desired petals and leaves is a
mutant whose phenotype except as to carotenoids can be
substantially the same as that of an adjacently-grown non-mutant
plant, or that phenotype can be different. In one aspect, a
contemplated marigold plant is a hybrid between another
contemplated mutant plant and a non-mutant in which the non-mutant
plant is a hybrid neither of whose parents are mutants.
[0039] Another aspect of the invention contemplates a marigold
plant, or a regenerable portion thereof, whose flower petals or
leaves or both contain one or more of an enhanced zeaxanthin ratio,
an enhanced neoxanthin plus violaxanthin ratio, an enhanced
.beta.-carotene ratio, an enhanced .alpha.-cryptoxanthin ratio, an
enhanced phytoene ratio or an enhanced phytofluene ratio and
preferably at least a zeaxanthin ratio that is greater than about
1:10, preferably greater than about 2:10, and up to about 1.0. The
petals of a contemplated plant typically contain a measurable
amount of zeta-carotene, as discussed before.
[0040] A contemplated plant in one embodiment is a hybrid or later
generation hybrid. A contemplated marigold plant of one aspect
contains an amount of xanthophylls, measured as the saponified
pigments extractable from the flowers that is about 4 to about 25
grams per kilogram of dry flowers or about 4 to about 25 mg/g dry
weight. A contemplated marigold of another aspect contains a lesser
xanthophyll content. The pollen and an ovule of such a plant are
separately contemplated. The regenerable portion of such a
contemplated plant comprises cells that include embryos, meristems,
pollen, leaves, anthers, roots, root tips, and flowers, or
protoplasts or callus derived therefrom.
[0041] Another embodiment contemplates a seed that on planting in a
suitable environment and growth to maturity yields a marigold plant
whose flower petals or leaves or both contain one or more of an
enhanced zeaxanthin ratio, an enhanced neoxanthin plus violaxanthin
ratio, an enhanced .beta.-carotene ratio, an enhanced
.alpha.-cryptoxanthin ratio, an enhanced phytoene ratio or an
enhanced phytofluene ratio and preferably at least a zeaxanthin
ratio that is greater than about 1:10, preferably greater than
about 2:10, and up to about 1.0. The petals of a contemplated plant
again typically contain a measurable amount of zeta-carotene,
typically at least 1 percent or more, as discussed before.
[0042] A mutant marigold plant oleoresin having one or more of an
enhanced zeaxanthin ratio, an enhanced neoxanthin plus violaxanthin
ratio, an enhanced .beta.-carotene ratio, an enhanced
.alpha.-cryptoxanthin ratio, an enhanced phytoene ratio or an
enhanced phytofluene ratio relative to an oleoresin from a
non-mutant marigold, and preferably at least a zeaxanthin ratio
that is greater than about 1:10, preferably greater than about
2:10, and up to about 1.0, is also contemplated. A contemplated
oleoresin also usually contains a measurable amount of
zeta-carotene, as discussed before.
[0043] A composition suitable for use as a food or feed supplement
is also contemplated. The food or feed supplement comprises a
mixture of zeaxanthin and lutein fatty acid esters dissolved or
dispersed in a comestible medium, wherein the zeaxanthin ratio is
greater than about 1:10, preferably greater than about 2:10, and up
to about 1.0. Another composition suitable for use as a food or
feed supplement comprises zeaxanthin and lutein dissolved or
dispersed in a comestible medium, wherein the zeaxanthin ratio is
greater than about 1:10, preferably greater than about 2:10, and up
to about 1.0.
BRIEF DESCRIPTION OF THE DRAWING
[0044] In the drawings forming a part of this disclosure,
[0045] FIG. 1 is a schematic representation of the biological
synthesis pathway for the production of lutein and zeaxanthin in
plants in which phytoene, the first C.sub.40 carotenoid in the
pathway, is converted in several steps (four arrows) to lycopene
and then the .gamma.-carotene that contains one .beta.-ring, after
which the pathway splits to form .alpha.-carotene that contains one
.epsilon.-ring and one .beta.-ring or .beta.-carotene that contains
two .beta.-rings, and after several steps, to lutein or zeaxanthin,
respectively, and the zeaxanthin branch continuing to the
epoxide-containing xanthophylls antheraxanthin, violaxanthin and
neoxanthin.
[0046] As used herein, the term "zeaxanthin ratio" is defined as
the quantity of zeaxanthin present in a dried flower petal or leaf
divided by the quantity of zeaxanthin plus lutein
[zeaxanthin/(lutein+zeaxanthin)] present in that petal or leaf. The
"neoxanthin plus violaxanthin ratio" is similarly calculated as the
ratio of neoxanthin+violaxanthin divided by the sum of those two
pigments plus lutein. The ".beta.-carotene ratio", the
".alpha.-cryptoxanthin ratio", the "phytoene ratio" and the
"phytofluene ratio" are similarly calculated using the appropriate
pigment amount as the numerator and the sum of either pigment plus
lutein as the denominator. Those pigment quantities are determined
by high performance liquid chromatography (HPLC) after
saponification of a dried flower petal or leaf extract as discussed
hereinafter so that the amount of each of lutein and zeaxanthin (or
other pigment) is measured in the free compound form, e.g., alcohol
form for lutein and zeaxanthin, present after saponification rather
than in the esterified form that is present in the fresh flower
petal, and chlorophyll that may be present in a leaf extract is
destroyed.
[0047] The word "oleoresin" is used herein to mean an extract of
plant tissues that contains plant pigments such as the xanthophylls
discussed herein in their esterified forms, sometimes accompanied
by amounts of other plant products and pigments such as other
carotenoids such as .beta.-carotene, as well as small amounts of
solvent such as hexane or acetone, typically less than 1 percent
organic solvent. Xanthophylls are typically present as mono- or
diesters in flower petals and are typically present as free
alcohols in marigold leaves. Carotenes such as .beta.-carotene or
lycopene are present as free, non-chemically-combined compounds.
Chlorophyll is present in marigold leaves and largely absent in the
petals. Thus, an oleoresin prepared from flower petals contains
xanthophyll esters and is largely free of chlorophyll, whereas an
oleoresin prepared from marigold leaves contains chlorophyll and
free xanthophylls. Both chlorophyll and xanthophyll esters are
decomposed by saponification of the oleoresin. A contemplated
oleoresin is a solid or semi-solid material.
DETAILED DESCRIPTION OF THE INVENTION
[0048] The present invention contemplates marigold plants, seeds,
flower petals, leaves and materials that can be prepared therefrom.
A contemplated plant additionally has flower petals, leaves or both
that contain an enhanced carotenoid ratio as compared to previously
known marigold plants. The petals and/or leaves of a contemplated
plant thus contain one or more of an enhanced zeaxanthin ratio, an
enhanced neoxanthin plus violaxanthin ratio, an enhanced
.beta.-carotene ratio, an enhanced .alpha.-cryptoxanthin ratio, an
enhanced phytoene ratio or an enhanced phytofluene ratio. The
leaves of a contemplated plant can be free of lutein. These
contemplated marigold plants are T. erecta, as compared to T.
patula or T. tenuifolia, or other Tagetes species. In addition, a
contemplated plant can be a xanthophyll marigold, as such plants
have been described before and are understood by workers of skill
in this art.
[0049] The usual ratio of zeaxanthin to zeaxanthin+lutein in
marigold petals is on the order of about 1:15 to about 1:25, so
that when only zeaxanthin and lutein amounts are used for
calculations, zeaxanthin is about 5 to about 7 percent of the
amount of lutein plus zeaxanthin. An article by Quackenbush et al.,
J. Assoc. Off. Agri. Chem., 55:617-621 (1972) reported a zeaxanthin
to lutein ratio in one group of American yellow T. erecta marigold
flower petals that was unusually high at about 1:4.4, whereas the
total concentration of xanthophylls in those petals was unusually
low at about 0.4 mg/g dry weight. A Mexican variety was said by
those authors to contain 11.1 percent zeaxanthin when lyophilized
petals were assayed and 3.8 percent when fresh petals were assayed.
The higher value is not in keeping with the remainder of the data
and is believed to be incorrect. The preferred zeaxanthin ratio in
petals contemplated here is even larger, being greater than about
1:10 and preferably greater than about 2:10, as will be discussed
hereinbelow, and the amount of petal xanthophylls is preferably at
least about 4 mg/g dry weight.
[0050] A contemplated marigold plant has flower petals that contain
a zeaxanthin ratio greater than about 1:10 and preferably greater
than about 2:10. More preferably still, a contemplated marigold
plant has flower petals that contain a zeaxanthin ratio greater
than about 3:10. Most preferably, that ratio is greater than 5:10,
and can be about 1.0. The flower from which the petals are taken
has a xanthophyll content of about 4 to about 25 mg/g dry weight,
and preferably about 10 to about 20 mg/g dry weight. Such a
marigold plant also preferably has leaves that contain a zeaxanthin
ratio greater than about 1:10 and preferably greater than about
2:10. More preferably still, a contemplated marigold plant has
leaves that contain a zeaxanthin ratio greater than about 3:10.
Most preferably, that ratio is greater than 5:10, and can be about
1.0. The contemplated leaves have a xanthophyll content of about
0.2 to about 1.25 mg/g dry weight, and preferably about 0.5 to
about 1 mg/g dry weight.
[0051] In some embodiments, the lutein concentration of the petals
of a contemplated plant contain about 80 to about 90 percent of the
lutein present in a parental, non-mutant plant. In other
embodiments, the amount of lutein is less than about 75 percent of
that present in a non-mutant plant. In still further embodiments,
the amount of lutein present in the flower petals is less than
about 15 percent of that present in the petals of a non-mutant
marigold plant.
[0052] A contemplated marigold can also exhibit differences in
ratios of one or more other pigments relative to lutein. Thus, the
neoxanthin plus violaxanthin ratio in a parental plant can be about
0.01 to about 0.022 for a non-mutant petal extract and about 0.17
to about 0.33 in leaves. That ratio in contemplated mutant plant
petals and leaves of one preferred embodiment is about 1:5 (0.2) to
about 1:1 (1). Neoxanthin and violaxanthin are measured together as
they are difficult to separate chromatographically.
[0053] The .beta.-carotene ratio in non-mutant plants is typically
about less than 0.007 for flower petals and about 0.3 to about 0.4
for leaves. That ratio is about 0.05 to about 0.9 for flower petals
and about one for leaves of mutant marigold plants.
[0054] .alpha.-Cryptoxanthin typically constitutes less than one
percent of colored carotenoids of non-mutant plant petals and the
.alpha.-cryptoxanthin ratio is consequently about 0.01 in
non-mutant flower petals. The .alpha.-cryptoxanthin ratio is about
0.25 to about 0.9 in the petals of some preferred mutated
plants.
[0055] Phytoene can be present in petals at about 3 to about 0.3
percent of the carotenoids in non-mutant plants and can be present
in at about 35 percent in some mutant flower petals that typically
contain a reduced amount of lutein. Exemplary phytoene ratios can
be from about 0.3 to about 1 in a contemplated plant as compared to
phytoene ratios of about 0.003 to about 0.03 in non-mutant plants.
Phytoene concentrations are largely unchanged in leaves of mutant
plants as compared to non-mutant plant leaves.
[0056] Phytofluene amounts in non-mutant plant petals are typically
about the same as those observed for phytoene, whereas the amount
present in the petals of a contemplated mutant plant is generally
about 40 to about 70 percent of the phytoene amount. The
phytofluene ratio for a non-mutant plant is usually about 0.005 to
about 0.03, whereas that ratio for a contemplated mutant plant is
about 0.2 to about 1. Phytofluene has not been observed in leaf
extracts.
[0057] The enhancements observed in the above ratios are typically
at least about two-fold. In particular embodiments, a ratio can be
enhanced by about ten- to about one hundred-fold.
[0058] The petals or leaves or both of a particular plant can have
one or more of the above-recited enhanced ratios. In usual
practice, two or more of the before-described enhanced ratios are
present. Thus, for example, the zeaxanthin ratio and the
.beta.-carotene ratio can be enhanced, or the zeaxanthin ratio and
the neoxanthin plus violaxanthin ratio can be enhanced. Similarly,
three or more of the ratios can be elevated.
[0059] .alpha.-Cryptoxanthin is a particularly interesting compound
in that it has been found to be present in relatively high levels
in a number of mutants and is not otherwise readily available.
Thus, .alpha.-cryptoxanthin was present at about 20 to about 40
percent of colored carotenoids in some mutants. The
.alpha.-cryptoxanthin ratio of such plants was consequently greatly
enhanced as compared to those plants whose petals contained more
usual amounts of carotenoids.
[0060] The petals of a contemplated plant typically contain a
measurable amount of zeta-carotene (.zeta.-carotene), whereas that
pigment is not present in a measurable amount; i.e., present at
less than 0.1 percent, in the petals of a non-mutant marigold
plant. Typically, zeta-carotene is present in an amount of at least
about 1 percent of the petal carotenoids. That amount of
zeta-carotene can be in the range of about 3 to about 7 percent in
some embodiments, and at about 20 percent in other embodiments.
[0061] As already noted, xanthophylls such as lutein and zeaxanthin
are present in flower petals primarily as mono- or diesters of
fatty acids such as lauric, myristic, palmitic, stearic, oleic or
the like, rather than as free compounds. As such, when a zeaxanthin
or other xanthophyll ratio is discussed herein, that ratio is
determined by extracting one or more flower petals with hexane or
other appropriate solvent to obtain a composition such as an
oleoresin comprised of esterified xanthophylls. That composition is
then saponified using a base such as potassium hydroxide to cleave
the esters and form free carotenoid alcohols. The free carotenoid
xanthophyll alcohols are thereafter separated from the
saponification reaction mixture and separated as desired using high
performance liquid chromatography (HPLC). The ratios of materials
present are determined by the areas under the appropriate HPLC
peaks using standard methods of integration.
[0062] The analytical method utilized herein to determine the
pigment ratios is exemplified hereinafter, and provides similar
results to those published by others, with different specific
techniques being used by different laboratories largely for reasons
of convenience. Using the procedure preferred here, flowers
approximately 98 percent fully opened are selected for analysis.
Petals are removed about one-third of the distance from the flower
center from the selected flowers.
[0063] Leaves can be harvested and extracted at substantially any
time. Xanthophylls are typically present as free compounds in
leaves as are carotenes. Chlorophyll present in leaves is also
extracted with the carotenoid pigments so assays are carried out
after saponification of the extract as that treatment destroys
chlorophyll. Leaves are assayed for carotenoid content as are the
petals.
[0064] A standard analytical method used in the industry for
determining carotenoid levels in plant extracts is that of the AOAC
1984, Official Methods of Analysis (14.sup.th ed), the Association
of Official Analytical Chemists, Arlington, Va., USA, the results
of whose assays are similar to those obtained herein.
[0065] A contemplated marigold plant is a mutant of a parental
line. That is, a first line or cross or seed is treated with a
mutagen (mutagenized) to provide a mutagenized plant that is
typically self-pollinated (selfed) one or more times. A plant
contemplated herein can arise from the mutagenesis itself, from one
of the selfings or from a cross of a mutagenized plant or offspring
with another mutagenized or non-mutagenized plant.
[0066] Substantially any kind of mutagen can be used to produce a
contemplated plant, and exemplary mutagens are discussed
hereinafter. Although some contemplated mutant marigolds have a
phenotype that is substantially different from that of
adjacently-grown non-mutant marigold parental plant, other
contemplated mutants exhibit substantially the same phenotype as
that of an adjacently-grown non-mutant parental plant, except for
phenotypic traits related to carotenoids. More specifically for the
latter plants, when one compares plant properties such as plant
height, plant diameter, flower head diameter, flower head height,
time to flowering, branching amount, length of branches, flower
stalk length, hypocotyl length, cotyledon length and cotyledon
width between a parent and a mutant plant, the values of those
properties for some contemplated mutant plants are each within
about 90 percent of those of the parental plant, including the
standard deviations in the measurements. More preferably, the
values for those properties of the mutant are within about 95
percent of the parent, and most preferably, the values are the
same, within the standard deviation. On the other hand, other
mutant plants differ greatly in one or more phenotypic traits.
[0067] A carotenoid-related phenotypic difference between the
parental and mutant plants is the quantity of xanthophyll pigment
that can be obtained from the flowers of the mutant. Parental
plants such as `Scarletade` or `Deep Orangeade` typically have
about 10 to about 18 mg/g dry whole flower head weight of
extractable xanthophyll pigments. A contemplated mutant plant
preferably contains about the same amount of carotenoid in the
flower petals, but can contain as little as about 4 mg/g dry
weight, particularly where the ratio of zeaxanthin to lutein is
very high such as about 9:1 or greater.
[0068] The leaves of a contemplated marigold can also exhibit a
phenotypic difference between the parental and mutant plants as to
the carotenoid content as well as one or more of the
before-discussed carotenoid ratios present in the leaves as
measured in a saponified oleoresin. The previously noted paper of
Moehs et al., Plant Mol. Biol., 45:281-293 (2001) reported that
leaf carotenoid ratios and contents were constant, whereas
carotenoid concentration in the petals differed. Here, it is found
that one or more of the before-mentioned zeaxanthin ratio,
antheraxanthin ratio, neoxanthin plus violaxanthin ratio, phytoene
ratio, phytofluene ratio, .beta.-carotene ratio and
.alpha.-cryptoxanthin ratio in mutant plants differed considerably
from parental non-mutant plants. In addition, the petals of each of
the mutant plants examined exhibited a measurable amount of
zeta-carotene, whereas no measurable amount zeta-carotene was
observed to be present in the parental non-mutant plants.
[0069] Phenotypic comparisons are made between adjacently-grown
plants. As used herein, the term "adjacently-grown" is used to mean
plants grown under as similar conditions of light, heat, growth
medium, humidity and nutrients as can be achieved so that growth
conditions do not govern the phenotype. For greenhouse-grown
plants, "adjacently-grown" means plants grown under conditions as
similar as possible on the same bench. For field-grown plants,
"adjacently-grown" means plants grown under conditions as similar
as possible in the same or adjoining fields.
[0070] Mutagenic agents useful for altering plants are well known
in the art, as are methods of using such agents. Exemplary chemical
mutagens include nitrosomethylurea (NMU), ethyl methanesulfonate
(EMS), methyl methanesulfonate, diethyl sulfate, nitrosoguanidine,
and ethylnitrosourea of which EMS is preferred herein. NMU can be
used as discussed in Cetl et al., Folia Fac. Sci. Nat. Univ.
Purkynianae Brun. Biol., 21(1): 5-56 (1980), whereas EMS is
typically utilized at about 0.25 to about 1 percent by volume
(v/v), and preferably at about 0.2 to about 0.8 percent. Gamma
irradiation is also a useful mutagenic agent when used to irradiate
seeds at a dose of 200 to about 20,000 rads (0.2 to about 20
krads).
[0071] Regardless of the mutagen used, the phenotype of the
resulting mutant plant, including carotenoid-related traits such as
the zeaxanthin ratio and the amount of xanthophylls in the petals,
is usually substantially identical to that of the parent, so that a
very large percentage of the mutants obtained are not useful. In
addition, plants seeming to have the same phenotype as the parent
need to be screened to locate a desired mutant plant. Those
screenings, although tedious, are routinely carried out and involve
analysis of carotenoid pigments from one or more single flower
petals or leaves or both. Thus, the preparation of a desired mutant
is a relatively rare, but repeatable event. For example, in one
study herein, only twenty-three useful mutants were obtained from
almost 22,000 mutant plants examined. In another study, about
twenty-four useful mutants out of about 8,200 examined plants were
obtained.
[0072] As already noted, a contemplated plant can be a plant that
grows from the mutagenized seed or can be a selfing or cross. In
one preferred embodiment, a contemplated marigold is a hybrid
formed by crossing the flowers of two plants that arose from two
different mutagenized plants from independent M.sub.1 plants
(M.sub.2.times.M.sub.2). In another embodiment, a contemplated
marigold is a hybrid formed by crossing the flowers of one plant
that arose from one mutagenized plant with a non-mutagenized plant.
In still another embodiment, a contemplated plant is a hybrid
formed by back-crossing a hybrid with one or the other of its
immediate parental flowers. The product of the crossing of two
different hybrid plants is contemplated as is the product of the
selfing of a hybrid.
[0073] The present invention also contemplates the pollen and an
ovule of a contemplated plant. The regenerable portion of a
contemplated plant is also itself contemplated and includes cells
selected from the group consisting of embryos, meristems, pollen,
leaves, anthers, roots, root tips, and flowers, or protoplasts or
callus derived therefrom. Methods for regenerating plants from
cells are well known to those skilled in the art, and
dicotyledonous plants such as marigolds are particularly amenable
to such regeneration.
[0074] A marigold oleoresin comprised of fatty acid esters of
lutein and zeaxanthin in which the zeaxanthin ratio is greater than
about 1:10 and preferably greater than about 2:10 is also
contemplated. More preferably, that ratio is greater than about
3:10 and is most preferably about 1.0. A contemplated marigold
oleoresin contains a zeaxanthin ratio as is present in the petals
or leaves of a contemplated marigold as discussed before.
Oleoresins are items of commerce and are sold to processers for
further treatment in the production of human or other animal food
or feed supplements. A contemplated oleoresin also typically
contains a measurable amount of zeta-carotene.
[0075] In an illustrative marigold oleoresin preparation,
xanthophyll esters; i.e., zeaxanthin or mixture of zeaxanthin and
lutein esters and possibly other xanthophyll esters and carotenes
such as zeta-carotene, are extracted from dried marigold flowers
with hexane, acetone, ethyl acetate, toluene, tetrahydrofuran (THF)
and the like organic solvent, or a mixture thereof. The extraction
is carried out according to procedures known in the art. The
solvent(s) is removed, resulting in an extract that typically
contains a high level of the xanthophyll esters and is about 99
percent and preferably about 99.9 percent free of the extracting
organic solvent; i.e., contains less than about 1 percent and
preferably less than about 0.1 percent organic solvent by weight.
The resulting solvent-free extract is referred to as a marigold
oleoresin. A leaf extract is similarly prepared, and contains free
xanthophylls, carotenes and chlorophyll.
[0076] A composition suitable for use as a food or feed supplement
for human or other animals such as poultry like chickens and
turkeys, fish like trout and salmon and crustaceans like shrimp,
lobsters and crabs is also contemplated. A contemplated food or
feed supplement can be used to provide color to the skin and fat of
those animals as well as to the egg yolks of such animals, and
particularly chickens.
[0077] One food or feed supplement comprises a mixture of fatty
acid esters of zeaxanthin alone or zeaxanthin, lutein and other
carotenoids as are present in a marigold oleoresin. That mixture of
mostly fatty acid esters is dissolved or dispersed in a comestible
medium, wherein the zeaxanthin and lutein fatty acid esters are
present at a zeaxanthin ratio that is greater than about 1:10,
preferably greater than about 2:10, more preferably greater than
about 3:10, and up to about 1.0. This food or feed supplement can
thus be prepared by suitable purification of a before-described
oleoresin as by dissolution and filtration, followed by dissolution
or dispersion of the purified mixed esters in an appropriate
comestible medium.
[0078] In some embodiments, the comestible medium is an edible
triglyceride oil, whereas in other embodiments the comestible
medium is a binding agent such as is frequently found in
pharmaceutical products such as pills and tablets (a
pharmaceutically acceptable binding agent). For tablets or
capsules, the xanthophyll ester content of the admixture measured
as free xanthophyll is typically about 0.1 to about 25 milligrams
per tablet or capsule, and more usually about 5 to about 20
milligrams per tablet or capsule.
[0079] Binding agents and adhesives preferably impart sufficient
cohesion to solids to permit normal processing such as sizing,
lubrication, compression and packaging, but still permit a tablet
or capsule to disintegrate and the composition to dissolve upon
ingestion. Exemplary binding agents include lactose monohydrate,
acacia, tragacanth, sucrose, gelatin, glucose, cellulose or
saccharide materials such as, but not limited to, microcrystalline
cellulose, croscarmellose sodium, hydroxypropyl methylcellulose
(HPMC), hydroxypropyl cellulose (Klucel.TM.), ethyl cellulose
(Ethocel.TM.), methyl cellulose and sodium carboxymethyl cellulose
(e.g., Tylose.TM.), pregelatinized starch (such as National.TM.
1511 and Starch 1500), polysaccharide acids, alginic acid and salts
of alginic acid, magnesium aluminum silicate, polyethylene glycol,
guar gum, bentonites, polyvinylpyrrolidone (povidone), and
polymethacrylates.
[0080] Exemplary edible oils include candelilia, coconut, cod
liver, cotton seed, menhaden, olive, palm, corn, soybean, peanut,
poppy seed, safflower and sunflower oil. The use of an oil having a
relatively high concentration of unsaturated fatty acids is
preferred; i.e., the use of an oil having an iodine value of about
100-150 is preferred. The admixture is typically carried out using
a high shear mixing apparatus, as is well known. Co-solvents and
additives such as ethanol and .alpha.-tocopherol, respectively, can
also be present as is noted in U.S. Pat. No. 5,382,714.
[0081] In another embodiment, the mixture of zeaxanthin and lutein,
zeaxanthin alone, or other carotenoid mixture is provided in the
form of generally spherical small pellets containing 0.5 to about
20 percent, and preferably about 1 to about 4 percent, of the
xanthophyll that are conventionally referred to as "beadlets".
These beadlets can be used admixed in a desired amount into human
food such as ready to eat cereals as is disclosed in U.S. Pat. No.
5,270,063 or admixed into chicken or other animal feed as are the
beadlets or other particles disclosed for the feed additive in U.S.
Pat. No. 5,849,345, No. 5,695,794, No. 5,605,699 and No.
5,043,170.
[0082] Exemplary beadlets are water-insoluble and are prepared by
encapsulation of a xanthophyll composition by cross-linked gelatin
or an alginate such as sodium alginate as is disclosed in U.S. Pat.
No. 4,670,247. A water insoluble beadlet containing the desired
carotenoid(s) is prepared by forming an emulsion containing the
carotenoid(s), water, gelatin, and a sugar. The emulsion is
converted into droplets that are individually collected in a mass
of starchy powder in such a manner that the particles from the
droplets are kept separated from each other until their particulate
form is permanently established. The carotenoid-containing
particles are separated from the starchy collecting powder, and
heat-treated at a temperature of about 90.degree. C. to about
180.degree. C. The heat treatment step insolubilizes the gelatin
matrix of the beadlet by a reaction between the carbonyl group of
the sugar with the free amino moieties of the gelatin molecule. The
resulting beadlets are water-insoluble and exhibit increased
stability to the stresses of feed pelleting. The cross-linking
process utilizes the ingredients employed in making the beadlet and
does not require addition of a cross-linking reagent or additive to
the composition.
[0083] U.S. Pat. No. 5,695,794 discloses another form of beadlets
that can be adapted for use herein as an additive for poultry feed.
Thus, beadlets having diameters of about 30 to about 55 microns are
prepared by spraying a molten solution of a desired amount of
carotenoid(s); i.e., zeaxanthin, a mixture of zeaxanthin and
lutein, or other carotenoid mixture described herein, in
hydrogenated vegetable oil such as hydrogenated cotton seed oil,
wheat-germ oil, safflower oil, soybean oil and the like, that also
can contain mono- and diglycerides such as those prepared from
hydrogenated soybean mono- and diglycerides, cottonseed mono- and
diglycerides and the like, as well as citric acid and
2,6-di-tert-butyl-4-methylphenol (BHT) as antioxidants. Other
antioxidants such as ethoxiquin, vitamin E and the like can also be
used, as is well known. The molten mixture is sprayed at a
temperature of about 160.degree. F. (about 70.degree. C.) into a
cyclonic airstream of a spray chiller such as available from Niro,
Inc., Columbia, Md. to produce the beadlets that solidify on
cooling. The cooled beadlets are dusted with an anticaking agent
such as fumed silica, calcium phosphate, powdered starch or
cellulose as are well known to form the beadlets that are
preferably added to the feed as supplement. An exemplary beadlet
contains about 10 to about 100 milligrams of zeaxanthin per gram
(mg/g) and preferably at about 10 to about 50 mg/g.
[0084] Animal feeds to which a contemplated zeaxanthin or
zeaxanthin-lutein mixture are added are well known in the art. The
above-noted U.S. Pat. No. 5,849,345, No. 5,695,794, No. 5,605,699
and No. 5,043,170 provide exemplary diets that are particularly
useful for poultry. U.S. Pat. No. 5,935,624 and No. 2,918,370
provide further illustrative poultry diets.
[0085] U.S. Pat. No. 5,258,189 teaches the addition of
.beta.-carotene to a ready to eat cereal product for humans in
which the .beta.-carotene is admixed with a cooked cereal product
dispersed in a vegetable oil or in dry form. Zeaxanthin or a
mixture of zeaxanthin and lutein as discussed elsewhere herein can
be used at a desired level in place of .beta.-carotene in a similar
food product.
[0086] Another composition suitable for use as a food or feed
supplement comprises a mixture of zeaxanthin and lutein dissolved
or dispersed in a comestible medium, wherein the zeaxanthin ratio
present is at a greater than about 1:10, preferably greater than
about 2:10, and up to about 1.0. This composition contains
saponified xanthophylls that are free zeaxanthin and lutein as
compared to the esters that are present in a marigold
oleoresin.
[0087] Methods are well known for saponifiying marigold oleoresins
to provide free xanthophylls. See, for example, Tyczkowski et al.,
Poultry Sci. 70(3): 651-654, 1991; and U.S. Pat. No. 5,382,714,
that lutein was crystallized from the saponified marigold oleoresin
by the addition of organic solvents.
[0088] In addition, Ausich et al. U.S. Pat. No. 5,648,564 teaches
the production of crystalline lutein from a marigold oleoresin by
admixing the oleoresin with a composition containing propylene
glycol and an aqueous alkali, preferably potassium hydroxide, to
form a reaction mixture of which oleoresin and propylene glycol
together constitute at least 75 weight percent. The reaction
mixture so formed is maintained at a temperature of about
65.degree. C. to about 80.degree. C. for a time period (typically
at least 3 hours) sufficient to saponify the xanthophyll ester and
form a saponified reaction mixture that contains free xanthophyll
in the form of crystals. The saponified extract is admixed with a
diluting amount of water to dissolve the water-soluble impurities
and reduce the viscosity of the reaction mixture. The diluted
admixture is gently admixed until homogeneous and then filtered to
collect the xanthophyll crystals. The collected xanthophyll
crystals are washed with warm water, and dried. No organic solvent
other than propylene glycol is used in the isolation and
purification of the xanthophyll from the xanthophyll
ester-containing oleoresin. The dried xanthophyll crystals so
formed are typically admixed with a comestible medium such as the
triglyceride discussed above. The xanthophyll content of the
admixture is typically about 0.1 to about 35 percent by weight, and
preferably about one to about ten percent by weight.
[0089] Without further elaboration, it is believed that one skilled
in the art can, using the preceding description, utilize the
present invention to its fullest extent. The following preferred
specific embodiments are, therefore, to be construed as merely
illustrative, and not limiting of the remainder of the disclosure
in any way whatsoever.
EXAMPLE 1
EMS Treatment of Tagetes erecta `Scarletade`
[0090] Seeds of Tagetes erecta xanthophyll marigold denominated
`Scarletade` (commercially available from PanAmerican Seed Co. 622
Town Road, West Chicago, Ill. 60185) were treated with ethyl
methanesulfonate (EMS, commercially available from Sigma Chemical
Co., St. Louis, Mo. 63178). Approximately 2,500 seeds were added to
400 ml of 0.4% (v/v) or 0.8% (v/v) EMS and were stirred gently for
eight hours at ambient temperature. During a four-hour period
following the EMS treatment, the seeds were washed sixteen times,
each wash using continuous stirring with 400 ml distilled water.
The treated seeds, identified as M.sub.1 seeds, were then sown in
trays containing soilless potting mix.
[0091] After several weeks, the seedlings were transplanted into
pots containing soilless potting mix and maintained in the
greenhouse. Flowers produced by those plants were naturally
self-pollinated. The resulting seeds, identified as M.sub.2 seeds,
were harvested from approximately 2,300 plants. Of these 2,300
plants, approximately 1,500 were grown from seeds treated with 0.4%
EMS and approximately 800 were grown from seeds treated with 0.8%
EMS. To facilitate identification of mutant plants, the M.sub.2
seeds from each of 50 M.sub.1 plants were combined into one lot,
resulting in a total of 47 seed lots. During the summer of the year
2000, 500 seeds from each of the 47 lots were sown and the
resulting plants were field-grown at PanAmerican Seed Co. in Santa
Paula, Calif. 93060.
EXAMPLE 2
HPLC Screening of EMS-Treated Tagetes erecta `Scarletade`
[0092] EMS-treated `Scarletade` plants were field-grown at
PanAmerican Seed Co. in Santa Paula, Calif. 93060, and were
screened by HPLC for altered zeaxanthin ratio. Flowers
approximately 98% fully opened were selected for analysis. From
each flower, one petal was removed one-third of the distance from
the flower center and placed in a 3.5".times.0.75" glass vial
containing approximately 5 grams of glass beads. Vials were
packaged with dry ice until stored at -80.degree. C.
[0093] For analysis, solvent delivery and aliquot removal were
accomplished with a robotic system comprising a single injector
valve Gilson 232XL and a 402 2S1V diluter [Gilson, Inc. USA, 3000
W. Beltline Highway, Middleton, Wis.]. For saponification, 3 ml of
50% potassium hydroxide hydro-ethanolic solution (4 water:1
ethanol) was added to each vial, followed by the addition of 3 ml
of octanol. The saponification treatment was conducted at room
temperature with vials maintained on an IKA HS 501 horizontal
shaker [Labworld-online, Inc. Wilmington, N.C.] for fifteen hours
at 250 movements/minute, followed by a stationary phase of
approximately one hour.
[0094] Following saponification, the supernatant was diluted with
0.9 ml of methanol. The addition of methanol was conducted under
pressure to ensure sample homogeneity. Using a 0.25 ml syringe, a
0.1 ml aliquot was removed and transferred to HPLC vials for
analysis.
[0095] For HPLC analysis, a Hewlett Packard 1100 HPLC, complete
with a quaternary pump, vacuum degassing system, six-way injection
valve, temperature regulated autosampler, column oven and
Photodiode Array detector was used [Agilent Technologies available
through Ultra Scientific Inc., 250 Smith Street, North Kingstown,
R.I.]. The column was a Waters YMC 30, 5-micron, 4.6.times.250 mm
with a guard column of the same material [Waters, 34 Maple Street,
Milford, Mass.]. The solvents for the mobile phase were 81
methanol:4 water:15 tetrahydrofuran (THF) stabilized with 0.2% BHT
(2,6-di-tert-butyl-4-methylphenol). Injections were 20 .mu.l.
Separation was isocratic at 30.degree. C. with a flow rate of 1.7
ml/minute. The peak responses were measured by absorbance at 447
nm.
[0096] Using this protocol, the results from the first 2,546
samples were statistically analyzed to establish average values for
lutein and zeaxanthin content. Because this was a semi-quantitative
analytical screen, peak area values were used. To identify a mutant
having a higher than average lutein and/or zeaxanthin
concentration, a value of three standard deviations greater than
the average was calculated. The calculated peak area means,
standard deviations and zeaxanthin ratios are shown in Table 1,
below.
1TABLE 1 Lutein and Zeaxanthin Confidence Interval Calculations
Peak Area Peak Area Statistic Lutein Zeaxanthin Ratio (%) Mean
775.0 41.6 5.03 Standard 263.2 16.4 0.71 deviation (sd) Mean + 3 sd
1564.6 90.9 7.16
[0097] Based on the above values, samples were selected having
lutein peak areas greater than 1565 and/or zeaxanthin peak areas
greater than 91. Samples were also selected only for high lutein
peak area, and for zeaxanthin ratios greater than 10 percent. A
total of 88 mutants were identified from 21,754 assayed samples
using these selection parameters. The total number of mutants
resulting from each EMS seed treatment is shown in Table 2,
below.
2TABLE 2 Correlation of `Scarletade` Mutants to EMS Treatment
Selection 0.4% EMS 0.8% EMS Total Parameter Treatment Treatment
Plants Zeaxanthin Ratio > 10% 10 13 23 Lutein > 1566 and 18
10 28 Zeaxanthin > 91 Lutein > 1566 and 20 7 27 Zeaxanthin
< 91 Lutein < 1566 and 7 3 10 Zeaxanthin > 91
[0098] More specific results of those assays as to relative levels
of lutein and zeaxanthin are shown in Table 3, below.
3TABLE 3 Identified `Scarletade` Mutants Plant Lutein Zeaxanthin
Percent Percent Identifier Area Area Zeaxanthin EMS Used 124-257
2.115 55.635 96.34 0.4 119-494 9.254 131.036 93.40 0.8 112-263
8.095 35.273 81.33 0.4 118-036 11.441 31.691 73.47 0.8 088-452 2.94
6.689 69.47 0.4 118-035 11.289 23.951 67.97 0.8 114-334 58.24
97.968 62.72 0.4 117-185 39.002 44.027 53.03 0.8 108-108 13.424
10.155 43.07 0.4 088-425 8.959 4.394 32.91 0.4 094-238 7.285 3.063
29.60 0.4 110-308 46.753 14.248 23.36 0.4 132-346 31.036 8.856
22.20 0.8 100-334 282.987 54.298 16.10 0.8 101-331 246.402 46.467
15.87 0.8 100-198 119.381 21.449 15.23 0.8 101-190 139.027 23.125
14.26 0.8 114-315 351.524 56.898 13.93 0.4 100-470 189.703 27.743
12.76 0.8 117-348 369.903 43.315 10.48 0.8 132-266 374.096 43.8
10.48 0.8 123-310 60.743 6.818 10.09 0.4 116-106 453.538 50.287
9.98 0.8
[0099] About 21,700 plants exhibited typical zeaxanthin ratios of
about 4 to about 7 percent (about 1:25 to about 1:15). The above
data illustrate the relative rarity of the mutations contemplated,
as well as the almost equal number of plants that exhibit reduced
zeaxanthin levels. The data also do not show a preference for the
use of one level of mutagen versus the other used here.
EXAMPLE 3
EMS Treatment of Tagetes erecta 13819
[0100] Seeds of Tagetes erecta xanthophyll marigold named 13819(a
proprietary breeding selection of PanAmerican Seed Co. 622 Town
Road, West Chicago, Ill. 60185) were treated with ethyl
methanesulfonate (EMS, commercially available from Sigma Chemical
Co. St. Louis, Mo. 63178). Approximately, 7,000 seeds were added to
600 ml of 0.2% (v/v) or 0.4% (v/v) EMS and stirred gently for eight
hours at ambient temperature. During a four-hour period following
the EMS treatment, the seeds were washed sixteen times, each wash
using continuous stirring with 600 ml distilled water.
[0101] The treated seeds, identified as M.sub.1 seeds, were then
sown in trays containing soilless potting mix. After three to four
weeks, the seedlings were transplanted into the field. Flowers
produced by these plants were bagged to prevent cross-pollination,
and were permitted to spontaneously self-pollinate. The resulting
seeds, identified as M.sub.2 seeds, were harvested from
approximately 2,391 plants. Of these plants, approximately 951 were
grown from seeds treated with 0.2% EMS and approximately 1,440 were
grown from seeds treated with 0.4% EMS.
[0102] To facilitate identification of mutant plants, the M.sub.2
seeds from each of 50 plants were combined into one lot. This
grouping resulted in a total of 48 seed lots. From late October
through mid-November of the year 2000, 1000 seeds from each of 15
lots of the 0.4% EMS treatment were sown and 700 plants of each lot
were greenhouse-grown at Seaview Nursery in El Rio, Calif. 93060.
In addition, 1,500 seeds from all of the 48 lots were sown in late
October of the year 2000, and 765 plants from each of the lots were
field-grown at Semillas Pan American Chile LTDA, in Pichidegua,
Chile.
EXAMPLE 4
HPLC Screening of EMS-Treated Tagetes erecta 13819
[0103] EMS-treated 13819 M.sub.2 plants were greenhouse-grown at
Seaview Nursery in El Rio, Calif. 93060 and field-grown at Semillas
PanAmerican Chile LTDA, in Pichidegua, Chile, and were screened for
altered zeaxanthin ratio. Flowers approximately 98% fully opened
were selected for analysis. From these flowers, petals were removed
one-third of the distance from the flower center. Approximately 100
mg of petal tissue was placed in plastic bags and stored frozen
until analysis. Dry weight was determined for two petals that were
placed in 3.5".times.0.75" glass vials containing approximately 5
grams of glass beads.
[0104] For analysis, solvent delivery and aliquot removal were
accomplished with a robotic system comprising a single injector
valve Gilson 232XL and a 402 2S1V diluter. For saponification, 3 ml
of 50% potassium hydroxide hydro-ethanolic solution (4 water:1
ethanol) was added to each vial, followed by the addition of 3 ml
octanol. The saponification treatment was conducted at room
temperature with vials maintained on an IKA HS 501 horizontal
shaker for fifteen hours at 250 movements per minute followed by a
stationary phase of approximately one hour.
[0105] Following saponification, the supernatant was diluted with
0.9 ml of methanol. The addition of methanol was conducted under
pressure to ensure sample homogeneity. Using a 0.25 ml syringe, a
0.1 ml aliquot was removed and transferred to HPLC vials for
analysis.
[0106] For HPLC analysis, a Hewlett Packard 1100 complete with a
quaternary pump, vacuum degassing system, six-way injection valve,
temperature regulated autosampler, column oven and Photodiode Array
detector was used. The column was a Waters YMC 30, 5-micron,
4.6.times.250 mm with a guard column of the same material.
Standards were obtained from DHI-Water & Environment, DK-2970
Horsholm, Denmark and Sigma Chemical Co., St. Louis, Mo. 63178. The
solvents for the mobile phase were 81 methanol:4 water:15
tetrahydrofuran stabilized with 0.2% BHT. Injections were 20 .mu.l.
Separation was isocratic at 30.degree. C. with a flow rate of 1.7
ml/minute. The peak responses were measured at 447 nm.
[0107] Using this protocol, the results from the first 507 samples
were statistically analyzed to establish average values for lutein
and zeaxanthin content. To identify a mutant having a higher or
lower than average lutein and zeaxanthin concentration, a value of
three standard deviations greater than or less than the average was
calculated. The calculated means, standard deviations and
zeaxanthin ratios are shown in Table 4, below.
4TABLE 4 Lutein and Zeaxanthin Confidence Interval Calculations
Lutein mg/g Zeaxanthin Lutein + Zeaxanthin Fresh mg/g Fresh mg/g
Fresh Ratio Statistic Weight Weight Weight (%) Mean 0.64 0.04 0.68
5.98 Standard 0.14 0.01 0.147 1.1 deviation Mean + 3 sd 1.06 0.07
1.12 9.28 Mean - 3 sd 0.22 0.007 0.24 2.68
[0108] Based on the above values, samples were selected having
zeaxanthin ratios greater than 10 percent, combined lutein and
zeaxanthin content greater than 1.12 mg/g fresh weight and combined
lutein and zeaxanthin content less than 0.24 mg/g fresh weight. A
total of 347 mutants were identified having a sum of lutein plus
zeaxanthin greater than 1.12 mg/g, and 43 mutants having a
zeaxanthin ratio greater than 10 percent were identified from 8192
samples using these selection parameters. The total number of
mutants resulting from each EMS seed treatment is shown in Table 5,
below.
5TABLE 5 Correlation of 13819 Mutants to EMS Treatment 0.2% EMS
0.4% EMS Total Selection Parameter Treatment Treatment Plants
Zeaxanthin 2 41 43 Ratio > 10% Lutein + Zeaxanthin > 1.12
mg/g 6 341 347 dry weight Lutein + Zeaxanthin < 0.24 mg/g 2 175
177 dry weight
[0109] Of the mutants having a zeaxanthin ratio greater than about
10 percent zeaxanthin, about 47 percent had between 10 and under 13
percent, whereas 53 percent exhibited 13 percent or greater.
EXAMPLE 5
Carotenoid Composition in Petals of Select Marigolds
[0110] Carotenoid compositions were determined for `Scarletade`
wild-type and mutant samples selected from those identified in the
screening procedure described in Example 2. Petal samples were
stored in a -80.degree. C. freezer until mutants were identified.
Samples were lyophilized, and the dried tissue was stored under
argon at -80.degree. C. until ready for analysis.
[0111] Extraction procedures were performed under red light. Dried
petals were ground to pass through a No. 40 sieve mesh size. A
ground sample was accurately weighed and transferred into a 100 ml
red volumetric flask. To the sample, 500 microliters (.mu.l) of
H.sub.2O were added, and the mixture was swirled for 1 minute.
Thirty ml of extractant solvent (10 ml hexane+7 ml acetone+6 ml
absolute alcohol+7 ml toluene) were added, and the flask was shaken
at 160 rpm for 10 minutes.
[0112] For saponification, 2 ml of 40% methanolic KOH were added
into the flask, which was then swirled for one minute. The flask
was placed in a 56.degree. C. H.sub.2O bath for 20 minutes. An air
condenser was attached to prevent loss of solvent. The sample was
cooled in the dark for one hour with the condenser attached. After
cooling, 30 ml of hexane were added, and the flask was shaken at
160 rpm for 10 minutes.
[0113] The shaken sample was diluted to volume (100 ml) with 10%
sodium sulfate solution and shaken vigorously for one minute. The
sample remained in the dark for at least 30 minutes. A 35 ml
aliquot was removed from the approximately 50 ml upper phase, and
transferred to a sample cup. An additional 30 ml of hexane were
added into the flask that was then shaken at 160 rpm for 10
minutes. After approximately one hour, the upper phases were
combined. For HPLC analysis, 10 ml aliquots were dried under
nitrogen and stored under argon at -80.degree. C.
[0114] HPLC equipment comprised an Alliance 2690 equipped with a
refrigerated autosampler, column heater and a Waters Photodiode
Array 996 detector (Waters Corp., 34 Maple Street Milford, Mass.
01757). Separation was obtained with a YMC C.sub.30 column, 3
.mu.m, 2.0.times.150 mm with a guard column of the same material.
Standards were obtained from ICC Indofine Chemicals Somerville,
N.J. 088876 and from DHI-Water & Environment, DK-2970 Horsholm,
Denmark.
[0115] The dried mutant samples were resuspended in tetrahydrofuran
and methanol to a total volume of 200 .mu.l and filtered, whereas
the control was not additionally concentrated. Carotenoids were
separated using a gradient method. Initial gradient conditions were
90% methanol:5% water:5% methyl tert-butyl ether at a flow rate of
0.4 milliliters per minute (ml/min). From zero to 15 minutes, the
mobile phase was changed from the initial conditions to 80
methanol:5 water:15 methyl tert-butyl ether, and from 15 to 60
minutes to 20 methanol:5 water:75 methyl tert-butyl ether. For the
following 10 minutes, the mobile phase was returned to the initial
conditions and the column equilibrated for an additional 10
minutes. The column temperature was maintained at 27.degree. C. and
the flow rate was 0.4 ml/minute. Injections were 10 .mu.l. The
majority of peak responses were measured at 450 nm and additional
areas added from 286, 348, 400 and 472 nm extracted channels.
[0116] Values for carotenoid profiles of selected mutants are
indicated in Tables 6a, 6b and 6c, below, using peak area as
percent of the total area. Indicated compound identifications are
based on spectra extracted and maximal absorbance in ethanol
(lambda maxima; ETOH) obtained for major peaks in each
chromatogram, some of which were verified by retention times of
known standards. Values combine suspected isomers of the same
compounds. Some compounds may contain minor impurities. Included in
the Table are values for yellow colored American marigolds (yellow
marigold) noted in Quackenbush et al., J. Assoc. Off. Anal. Chem.,
55(3):617-621 (1972). Single entries are used in Tables 6a-6c for
neoxanthin/violaxanthin and chrysanthemaxanthin/ flavoxanthin
compound pairs that could not be separated by the procedure used
here.
6TABLE 6a Relative Percent Distribution of Carotenoids in Petals of
Tagetes erecta and Mutants Wave- Marigold Selections length in
Yellow Carotenoid EtOH (nm) Marigold `Scarletade` 13819 117-185
124-257 119-494 112-263 118-035 088-425 325-444 Phytoene 276, 286,
2.4 0.3 0.3 6.8 7.0 1.0 11.0 12.3 34.3 30.9 297 Phytofluene 331,
348, 2.6 0.5 0.4 4.0 4.2 0.9 7.5 7.4 17.8 13.3 (isomers) 367
.zeta.-Carotene 377, 399, nf* <0.1 <0.1 5.6 5.3 1.3 6.9 6.8
18.2 17.1 (cis/trans 425 isomers) Neurosporene 416, 440, nr**
<0.1 <0.1 0.1 0.2 <0.1 <0.1 <0.1 3.5 3.5 470
Lycopene 447, 472, nr <0.1 <0.1 0.5 1.3 <0.1 <0.1
<0.1 1.0 2.8 504 .alpha.-Carotene 423, 444, 0.1 <0.1 <0.1
<0.1 <0.1 <0.1 <0.1 <0.1 0.8 1.2 473 .beta.-Carotene
425, 451, 0.5 <0.1 <0.1 4.4 6.8 2.3 0.6 0.3 2.3 4.8 478
Neoxanthin 415, 439, 0.8 1.5 4.1 13.3 12.8 16.7 4.3 3.5 0.7 1.1 467
Violaxanthin 419, 440, nr 470 Anthera- 422, 444, 0.1 3.1 5.5 12.5
14.4 19.2 4.1 4.5 0.9 1.5 xanthin 472 Lutein 420, 445, 72.3 84.9
81.7 13.3 1.3 <0.1 0.6 7.1 2.0 4.9 475 Zeaxanthin 428, 450, 16.4
4.7 5.9 21.3 30.6 35.7 16.5 18.2 2.0 4.0 478 .alpha.-Crypto- 421,
446, 0.8 <0.1 <0.1 <0.1 <0.1 <0.1 32.2 26.9 <0.1
0.2 xanthin 475 .beta.-Crypto- 428, 450, 0.5 <0.1 <0.1 0.5
0.6 0.8 0.2 0.4 1.9 1.8 xanthin 478 .beta.-Zeacarotene 406, 428,
0.5 not identified 454 Chrysanthema- 400, 421, 0.8 <0.1 <0.1
2.3 1.5 4.5 0.8 0.5 0.2 0.2 xanthin 448 Flavoxanthin 400, 421, 1.3
448 Auroxanthin 380, 401, 0.1 not identified 426 Other compounds
that 0.8 5.0 2.1 15.3 14.0 17.6 15.1 12.0 14.3 12.7 show absorbance
at 450 nm *nf = not found **nr = not reported
[0117]
7TABLE 6b Relative Percent Distribution of Carotenoids in Petals of
Tagetes erecta and Mutants Marigold Selections Wave-length in
Yellow Carotenoid EtOH (nm) Marigold `Scarletade` 13819 100-198
100-334 100-470 101-190 114-315 Phytoene 276, 286, 2.4 0.3 0.3 4.8
3.9 6.1 3.4 5.2 (isomers) 297 Phytofluene 331, 348, 2.6 0.5 0.4 3.2
3.2 3.8 3.2 3.3 (isomers) 367 .zeta.-Carotene 377, 399, nf* <0.1
<0.1 4.8 4.0 4.4 3.6 3.2 (cis/trans 425 isomers) Neurosporene
416, 440, nr** <0.1 <0.1 <0.1 <0.1 <0.1 <0.1
<0.1 470 Lycopene 447, 472, nr <0.1 <0.1 <0.1 <0.1
<0.1 <0.1 <0.1 504 .alpha.-Carotene 423, 444, 0.1 <0.1
<0.1 0.3 0.4 0.2 0.4 0.2 473 .beta.-Carotene 425, 451, 0.5
<0.1 <0.1 0.8 0.7 0.5 0.8 0.5 478 Neoxanthin 415, 439, 0.8
1.5 4.1 <0.2 0.3 <0.2 <0.2 <0.2 467 Violaxanthin 419,
440, nr 470 Anthera- 422, 444, 0.1 3.1 5.5 <0.2 <0.2 <0.2
<0.2 <0.2 xanthin 472 Lutein 420, 445, 72.3 84.9 81.7 68.0
70.7 67.5 71.1 71.6 475 Zeaxanthin 428, 450, 16.4 4.7 5.9 14.8 13.4
13.1 13.6 12.3 478 .alpha.-Crypto- 421, 446, 0.8 <0.1 <0.1
0.6 0.6 0.5 0.6 0.4 xanthin 475 .delta.-Carotene 431, 456, nr
<0.1 <0.1 0.5 0.2 0.8 0.4 0.5 489 .beta.-Crypto- 428, 450,
0.5 <0.1 <0.1 <0.2 <0.2 <0.2 <0.2 <0.2 xanthin
478 .beta.-zeacarotene 406, 428, 0.5 Not identified 454
Chrysanthema- 400, 421, 0.8 <0.1 <0.1 <0.2 <0.2 <0.2
<0.2 <0.2 xanthin 448 Flavoxanthin 400, 421, 1.3 448
Auroxanthin 380, 401, 0.1 Not identified 426 Other compounds that
0.8 5.0 2.1 2.1 2.6 2.9 2.8 2.7 show absorbance at 450 nm *nf = not
found **nr = not reported
[0118]
8TABLE 6c Relative Percent Distribution of Carotenoids in Petals of
Tagetes erecta and Mutants Marigold Selections Wave-length in
Yellow Carotenoid EtOH (nm) Marigold `Scarletade` 13819 126-415
098-240 098-394 115-004 Phytoene 276, 286, 2.4 0.3 0.3 11.8 10.0
8.6 13.0 (isomers) 297 Phytofluene 331, 348, 2.6 0.5 0.4 9.1 5.8
5.4 9.6 (isomers) 367 .zeta.-Carotene 377, 399, nf* <0.1 <0.1
5.0 3.6 3.5 10.3 (cis/trans 425 isomers) Neurosporene 416, 440,
nr** <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 470 Lycopene
447, 472, nr <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 504
.alpha.-Carotene 423, 444, nr <0.1 <0.1 0.5 0.4 0.4 0.6 473
.beta.-Carotene 425, 451, 0.5 <0.1 <0.1 0.1 0.1 0.1 <0.1
478 Neoxanthin 415, 439, 0.8 1.5 4.1 0.3 0.4 0.4 <0.1 467
Violaxanthin 419, 440, nr 470 Anthera- 422, 444, 0.1 3.1 5.5 1.7
1.9 2.2 1.9 xanthin 472 Lutein 420, 445, 72.3 84.9 81.7 61.7 70.1
71.0 52.3 475 Zeaxanthin 428, 450, 16.4 4.7 5.9 2.5 2.8 3.4 1.8 478
.alpha.-Crypto- 421, 446, 0.8 <0.1 <0.1 0.7 0.6 0.4 0.2
xanthin 475 .delta.-Carotene 431, 456, nr <0.1 <0.1 1.6 0.4
0.3 5.2 489 .beta.-Crypto- 428, 450, 0.1 <0.1 <0.1 <0.1
<0.1 <0.1 <0.1 xanthin 478 .beta.-Zeacarotene 406, 428,
0.5 Not identified 454 Chrysanthema- 400, 421, 0.8 <0.1 <0.1
<0.1 0.1 0.1 <0.1 xanthin 448 Flavoxanthin 400, 421, 1.4 448
Auroxanthin 380, 401, 0.1 Not identified 426 Other compounds that
0.8 5.0 2.1 4.9 3.7 4.19 4.8 show absorbance at 450 nm *nf = not
found **nr = not reported
EXAMPLE 6
Carotenoid Composition in Leaves of Select Marigolds
[0119] Leaves of several marigold plants were assayed for the
relative concentration of colored carotenoids present. Leaves from
`Scarletade` and 13819 were used as controls for comparison to
leaves from mutant plants. Assays were conducted as in Example 5
and are shown in Tables 7a and 7b, below, where single entries are
used for neoxanthin/violaxanthin and
chrysanthemaxanthin/flavoxanthin compound pairs that could not be
separated. Data in Tables 7a and 7b were collected from different
groups of plants grown under different conditions.
9TABLE 7a Relative Percent Distribution of Carotenoids in Leaves of
Tagetes erecta and Mutants Wave length in Marigold Selections
Carotenoid EtOH (nm) `Scarletade` 13819 124-257 119-494 117-185
086-013 Phytoene 276, 286, 0.1 0.4 0.5 0.2 0.2 0.5 297 Neoxanthin
415, 439, 9.2 17.6 36.3 22.7 26.8 11.6 467 Violaxanthin 419, 440,
470 Antheraxanthin 422, 444, 2.8 4.3 8.4 7.7 9.1 2.9 472 Lutein
420, 445, 44.3 37.8 0.5 <0.1 1.6 34.0 475 Zeaxanthin 428, 450,
6.6 3.8 4.6 27.5 10.6 4.1 478 .beta.-Carotene 425, 451, 22.6 26.5
34.1 25.0 32.7 35.8 478 .alpha.-Carotene 423, 444, 0.5 0.3 <0.1
<0.1 <0.1 0.2 473 Chrysanthema- 400, 421, 1.1 1.0 0.9 4.1 3.2
0.5 xanthin 448 Flavoxanthin 400, 421, 448 Other compounds that
12.8 8.3 14.7 12.7 15.8 10.4 show absorbance at 450 nm
[0120]
10TABLE 7b Relative Percent Distribution of Carotenoids in Leaves
of Tagetes erecta and Mutants Wave-length in Marigold Selections
Carotenoid EtOH (nm) `Scarletade` 100-198 100-334 100-470 101-190
114-315 Phytoene 276, 286, Inadequate Peak Separation 297
Neoxanthin 415, 439, 20.4 <0.1 0.3 <0.1 3.1 <0.1 467
Violaxanthin 419, 440, 470 Antheraxanthin 422, 444, 1.6 1.7 1.8 1.6
5.4 1.1 472 Lutein 420, 445, 48.3 24.7 27.6 28.8 27.7 24.3 475
Zeaxanthin 428, 450, 0.4 46.3 43.1 44.0 32.3 48.2 478
.beta.-Carotene 425, 451, 15.9 14.5 17.3 14.5 19.6 13.8 478
.alpha.-Carotene 423, 444, <0.1 <0.1 <0.1 <0.1 <0.1
<0.1 473 Chrysanthema- 400, 421, 1.0 <0.1 <0.1 <0.1
<0.1 <0.1 xanthin 448 Flavoxanthin 400, 421, 448
.beta.-Cryptoxanthin 428, 450, 0.3 0.3 0.3 0.6 0.3 0.9 478 Other
compounds that show 12.1 12.4 9.5 10.5 11.5 11.7 absorbance at 450
nm
[0121] Each of the patents and articles cited herein is
incorporated by reference. The use of the article "a" or "an" is
intended to include one or more.
[0122] The foregoing description and the examples are intended as
illustrative and are not to be taken as limiting. Still other
variations within the spirit and scope of this invention are
possible and will readily present themselves to those skilled in
the art.
* * * * *